Finalgon (nonivamid, nicoboxil) ointment 20 g.

Description

Finalgon Storage
active substances: nonivamide, nicoboxil;

1 g of ointment contains 4.0 mg of nonivamide and 25.0 mg of nicoboxil;

Excipients: diisopropyl adipate, colloidal anhydrous silica, white soft paraffin, sorbic acid, Ceylon citronella oil, purified water.

Finalgon Dosage form
Ointment.

Main physical and chemical properties: almost colorless or slightly brownish color, transparent or slightly opalescent soft homogeneous ointment with the smell of lemon oil.

Finalgon Pharmacotherapeutic group
Topical remedies for joint and muscle pain. Other remedies used topically for joint and muscle pain.

ATX code M02A X10.

Pharmacological properties
Finalgon contains two vasodilating active substances, which cause an intense feeling of heat on the skin, which is retained for several hours.

Vanilla vanilamide (nonivamide)

Nonyl vanilamide is a synthetic analogue of capsaicin with analgesic properties. These properties can be explained by the release of substance P in peripheral nociceptive C-fibers and A-delta nerve fibers after repeated application of the drug to the skin. By stimulating the corresponding nerve endings in the skin, nonyl vanilamide causes vasodilation of the surrounding blood vessels, which is accompanied by an intense long-lasting feeling of warmth.

Nicotinic acid beta-butoxyethyl ester (nicoboxyl)

Nicotinic acid is a B vitamin that has prostaglandin-mediated vasodilating properties. Nicotinic acid beta-butoxyethyl ester causes a rapid hyperemia effect, which is more intense than the nonyl vanillamide effect.

Combination

Nonivamide and nicoboxil have complementary vasodilating properties, which reduces the time from application to the onset of skin redness.

This increases the local blood circulation in the skin. Due to this, the drug Finalgon® causes a long-lasting feeling of warmth.

In a study of hemoglobin levels in the skin and adjacent muscles, topical nonivamide / nicoboxil increased both oxidized hemoglobin concentrations and oxygen saturation of the treated skin. Concentrations of oxidized hemoglobin also increased in the adjacent muscle. These effects were observed within 15 minutes after drug administration and occurred faster in the skin and were more intense than in muscle. Topical application of nonivamide / nicoboxil increased blood circulation in the blood vessels of the skin and muscles.

One clinical study demonstrated the analgesic effect of Finalgon® ointment (0.4% nonivamide plus 2.5% nicoboxil) in acute back pain. Patients who received Finalgon® ointment (on a strip of ointment 2 cm long up to 3 times a day with a duration of the drug not more than 4 days), noted clinically significant relief of back pain 4 hours after the first application of the drug and a significant reduction in pain on the last day treatment. Pain reduction began 1 – 2 hours after the first application of the drug.

Pharmacokinetics.

The drug Finalgon® is applied topically, and its clinical effect is manifested at the application site. In this regard, data on systemic pharmacokinetics are missing.

The reaction to the drug (erythema and fever) occurs a few minutes after application, which indicates the rapid penetration of active substances through the skin.

Indication
For topical treatment of joint and muscle pain.

Contraindication
Hypersensitivity to the active substances or to other components of the drug;
very sensitive skin;
open wounds;
dermatitis;
skin diseases.